C-octahydroquinolizin-1-yl-methylamine | 22342-32-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹嗪类
• 英文名称: C-octahydroquinolizin-1-yl-methylamine
• 英文别名: C-Octahydrochinolizin-1-yl-methylamin；(Ξ)-11-Amino-lupinan；1-Aminomethyl-chinolizidin；α-Amino-lupinan；Aminolupinan；2H-Quinolizine-1-methanamine, octahydro-；2,3,4,6,7,8,9,9a-octahydro-1H-quinolizin-1-ylmethanamine
• CAS: 22342-32-1
• 化学式: C₁₀H₂₀N₂
• mdl: MFCD00995440
• 分子量: 168.282
• InChiKey: WSBDCEJEINRUML-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  C-octahydroquinolizin-1-yl-methylamine 、 乙酰氯 以94%的产率得到
  参考文献：
  名称：

  ABDUVAXABOV, A. A.;TLEGENOV, R. T.;DALIMOV, D. N.;XAITBAEV, X.;TILYABAEV,+, UZB. XIM. ZH.,(1991) N, S. 43-46

  摘要：

  DOI：
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 氨 作用下， 生成 C-octahydroquinolizin-1-yl-methylamine
  参考文献：
  名称：

  DE401167

  摘要：

  公开号：

文献信息

• NOVEL BENZAMIDE DERIVATIVE AND USE THEREOF
  申请人：VIVOZON, INC.

  公开号：US20140336378A1

  公开（公告）日：2014-11-13

  Disclosed are a novel benzamide derivative and pharmaceutical use thereof, and more particularly, a novel benzamide derivative having a structure of Formula 1 or pharmaceutically acceptable salts thereof, and a composition for prevention or treatment of pain or itching including the above material. The novel benzamide derivative and pharmaceutically acceptable salt thereof according to the present invention exhibit excellent pain-suppressive effect and, in particular, pain-suppressive effect in not only a neuropathic animal model but also other models such as a formalin model, and therefore, may be used in suppression of different pains such as nociceptive pain, chronic pain, etc. Further, since it was demonstrated that the present invention displays anti-pruritic efficacy even in an itching model, to which a mechanism and treatment concept established with respect to pain is applied, the present invention may also be effectively used in radical treatment of atopic dermatitis by applying the inventive product to an anti-pruritic composition in order to suppress an initial itching stage and treat symptoms thereof, thus preventing skin damage or inflammation after the scratching stage.

  揭示了一种新的苯甲酰胺衍生物及其药用，更具体地说，一种具有化学式1结构或其药用盐的新苯甲酰胺衍生物，以及包括上述材料的用于预防或治疗疼痛或瘙痒的组合物。根据本发明，所述新的苯甲酰胺衍生物及其药用盐表现出优异的镇痛效果，特别是在不仅神经病理动物模型中而且其他模型如福尔马林模型中表现出的镇痛效果，因此，可用于抑制不同类型的疼痛，如伤害性疼痛、慢性疼痛等。此外，由于证明了本发明在瘙痒模型中显示出抗瘙痒功效，应用于疼痛方面建立的机制和治疗概念，因此，本发明还可通过将创新产品应用于抗瘙痒组合物中，以抑制初始瘙痒阶段并治疗其症状，从而预防刮痒阶段后的皮肤损伤或炎症。
• [EN] PROTEIN KINASE C INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE LA PROTÉINE KINASE C ET UTILISATIONS DE CEUX-CI
  申请人：RIGEL PHARMACEUTICALS INC

  公开号：WO2014089112A1

  公开（公告）日：2014-06-12

  This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  这份披露涉及一些化合物，它们可作为蛋白激酶C（PKC）的抑制剂，因此可用于治疗通过PKC的活性介导或维持的各种疾病和疾病。这份披露还涉及包括这些化合物的药物组合物，使用这些化合物治疗各种疾病和疾病的方法，制备这些化合物的过程以及在这些过程中有用的中间体。
• A new method for the synthesis of 5-amidinobarbiturates
  作者：I. V. Paramonov、N. A. Belyaev、V. A. Bakulev

  DOI：10.1007/s11172-007-0253-3

  日期：2007.8

  The reactions of 5-[arylamino(methylthio)methylene]pyrimidine-2,4,6(1H,3H,5H)-triones with different aliphatic and aromatic amines were studied. A series of 5-amidinobarbiturates was synthesized. A new and preparatively convenient method for their synthesis appropriate for the use in the combinatorial chemistry was developed.

  研究了5-[芳基氨基(甲硫基)亚甲基]嘧啶-2,4,6(1H,3H,5H)-triones与不同脂肪族和芳香族胺的反应。合成了一系列 5-脒基巴比妥酸盐。开发了一种新的、制备方便的合成方法，适用于组合化学。
• PROTEIN KINASE C INHIBITORS AND USES THEREOF
  申请人：RIGEL PHARMACEUTICALS, INC.

  公开号：US20140163022A1

  公开（公告）日：2014-06-12

  This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  本公开涉及的化合物可用作蛋白激酶C（PKC）的抑制剂，因此可用于治疗通过PKC活性介导或维持的各种疾病和障碍。本公开还涉及包括这些化合物的药物组合物，使用这些化合物治疗各种疾病和障碍的方法，制备这些化合物的过程以及这些过程中有用的中间体。
• PAGLIETTI G.; BOIDO V.; SPARATORE F., FARMACO, ED. SCI. <FRPS-AX>, 1975, 30, NO 6, 505-511
  作者：PAGLIETTI G.、 BOIDO V.、 SPARATORE F.

  DOI：——

  日期：——